Navigation Links
A*STAR scientists score 'hat-trick' against cancer

Scientists from Singapore's Agency of Science, Technology and Research (A*STAR) have made three successive breakthroughs in key areas of cancer research. Their work, published in top scientific journals Cancer Cell, Nature Cell Biology, and Cancer Research, sheds light on the mechanism behind cancer metastasis, suggest why breast cancer cells live as long as they do, and show a better way to detect and fight cervical cancer.

Stopping the spread of cancer

A team of scientists led by Dr Zeng Qi , from A*STAR's Institute of Molecular and Cell Biology (IMCB) has made a discovery about how PRL-3, a protein that plays a key role in tumorigenesis and cancer metastasis, is regulated in the body by PCBP1. Together with her collaborator Dr. Leah Vardy from A*STAR's Institute of Molecular Biology (IMB), the scientists found that PCBP1 impedes the translation of PRL-3 mRNA. Their discovery, published today in the leading journal Cancer Cell, sheds light on the role of PRL-3 in cancer and suggests possible ways to prevent metastasis, arguably the most pernicious and harmful aspect of the disease.

PRL-3 was first identified by Dr Zeng in 1998. However, the mechanism controlling the expression of PRL-3 is poorly understood. While trying to understand how PRL-3 expression is regulated in the body, the scientist discovered that PCBP1 was responsible for suppressing the expression of PRL-3. Using their mouse model, the scientists found that inducing over-expression of PCBP1 significantly reduced tumour size, suggesting that controlling levels of PCBP1 may be a means of suppressing the growth and spread of tumours in the body.

Said Dr Zeng, "The finding of PCBP1 as a potential tumor suppressor is highly significant as a similar mechanism may be regulating other cancer genes. Since PRL-3 plays multiple tasks in contributing to cancer metastasis, we are extremely excited to discover the mechanism underlying PRL-3's expression control as it uncovers another piece of the puzzle surrounding one of the most important proteins involved in cancer."

Their findings were praised by Prof Neal Copeland, Executive Director of IMCB, who said, "This study by Drs Zeng and Vardy is a fine example of how basic research contributes to understanding processes that lead to metastasis, perhaps the most devastating aspect of cancer. There are many facets of the disease which still remain obscure at the cellular and molecular level, and this sort of painstaking research is needed in the fight against cancer."

Dr Zeng aims to undertake more research to elucidate the regulatory mechanisms surrounding PRL-3. "PRL-3's association with diverse human cancers makes it an excellent therapeutic target. An increased understanding of PRL-3 will definitely help us develop strategies to block PRL-3 expression or inhibit its activity and thus prevent it from promoting cancer metastasis, allowing us to deal a heavy blow to this most dreaded human disease," added Dr Zeng.

Shortening the life of breast cancer

Another team of scientists from IMCB led by Dr Vinay Tergaonkar have discovered a protein, Rap1, which plays an important role in breast cancer. Their work, published in Nature Cell Biology showed that the presence and abundance of Rap1 could serve as biomarkers of various human illnesses including breast cancer. They also found that Rap1 could protect cancer cells from self-programmed cell death and that Rap1 levels in breast tumours might be responsible for cancer cell metastasis, making the protein an excellent target for cancer therapies.

A more sensitive test for cervical cancer

The third team of scientists led by Dr Francoise Thierry of IMB discovered that the human papillomavirus (HPV) E2 protein could be used for the early detection of HPV . Their work, published in Cancer Research, is a step forward in the fight against cervical cancer, the second cause of death by cancer in women worldwide. Dr Thierry, together with Drs Jeffrey Low and Diana Lim of the National University Health System, Singapore, showed that HPV detection methods based on HPV E2 were more sensitive than methods based on detection of the HPV DNA. Furthermore, the presence of HPV E2 was intimately linked to the progression of cervical cancer, and could therefore help to control the progression of the disease.


Contact: Joshua Tan
Agency for Science, Technology and Research (A*STAR), Singapore

Related biology news :

1. Scientists use computer algorithms to develop seasonal flu vaccines
2. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists
3. PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies
4. Scientists describe 2 new species of fish from area engulfed by oil spill
5. Marine scientists return with rare creatures from the deep
6. Scientists find direct line from development to growth
7. UM School of Medicine scientists develop new strategy that may improve cognition
8. Honey as an antibiotic: Scientists identify a secret ingredient in honey that kills bacteria
9. NOAA-supported scientists predict larger than average Gulf dead zone
10. SAGE to publish the Bulletin of the Atomic Scientists
11. Scientists call on US to stem ecological impact of trade in coral reef wildlife
Post Your Comments:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: